(917) 441-2344

PayPal can be used to send payment for services:

©2018 by Mark W. Wilson, MD, PC. Proudly created with

"The Prevalence of Anxiety Disorders During Pregnancy and the Postpartum Period: A Multivariate Bayesian Meta-Analysis"

September 2, 2019

"Emily J Fawcett, Nichole Fairbrother, Megan L Cox, Ian R White, Jonathan M Fawcett

Journal of Clinical Psychiatry 2019 July 23, 80 (4)


OBJECTIVE: To estimate the prevalence of anxiety disorders in pregnant and postpartum women and identify predictors accounting for variability across estimates.


DATA SOURCES: An electronic search of PsycINFO and PubMed was conducted from inception until July 2016, without date or language restrictions, and supplemented by articles referenced in the obtained sources. A Boolean search phrase utilized a combination of keywords related to pregnancy, postpartum, prevalence, and specific anxiety disorders.


STUDY SELECTION: Articles reporting the prevalence of 1 or more of 8 common anxiety disorders in pregnant or postpartum women were included. A total of 2,613 records were retrieved, with 26 studies ultimately included.


DATA EXTRACTION: Anxiety disorder prevalence and potential predictor variables (eg, parity) were extracted from each study. A Bayesian multivariate modeling approach estimated the prevalence and between-study heterogeneity of each disorder and the prevalence of having 1 or more anxiety disorder.


RESULTS: Individual disorder prevalence estimates ranged from 1.1% for posttraumatic stress disorder to 4.8% for specific phobia, with the prevalence of having at least 1 or more anxiety disorder estimated to be 20.7% (95% highest density interval [16.7% to 25.4%]). Substantial between-study heterogeneity was observed, suggesting that "true" prevalence varies broadly across samples. There was evidence of a small (3.1%) tendency for pregnant women to be more susceptible to anxiety disorders than postpartum women.


CONCLUSIONS: Peripartum anxiety disorders are more prevalent than previously thought, with 1 in 5 women in a typical sample meeting diagnostic criteria for at least 1 disorder. These findings highlight the need for anxiety screening, education, and referral in obstetrics and gynecology settings."

Please reload

Our Recent Posts

Below is an updated consent for telehealth; you can obtain the official form from my assistant Eric Scott Kincaid.  I added in the following (listed a...

Updated Consent for Telehealth

March 24, 2020

Hi everyone,

I know you’re all closely watching the new developments in the COVID-19 pandemic and I imagine you’ve seen the recent guidelines that sugg...

COVID-19/coronavirus update

March 15, 2020

For those folks taking lamotrigine (Lamictal), if your generic brand is Taro Pharmaceuticals, there is a recall (due to inactive ingredients that may...

Recall of specific generic brand of lamotrigine (Lamictal)

January 26, 2020

Please reload


I'm busy working on my blog posts. Watch this space!

Please reload